Drug Trial Radar · NCT03075696
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
940
Planned (sponsor's estimate)
Start
Feb 21, 2017
Primary completion
Mar 30, 2029
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-into-human (EIH) study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-participant dose-escalation cohorts will be used in Part I, followed by conversion to multiple participant dose-escalation cohorts (Part II), in order to define a tentative maximum tolerated dose (MTD) or optimal biological dose (OBD). The expansion cohorts (Part III) will be initiated when the tentative MTD/OBD is defined, to further evaluate the safety, PK and therapeutic activity of glofitamab.
Conditions
- Non-Hodgkin's Lymphoma
Interventions
GlofitamabDrug
Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
ObinutuzumabDrug
Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.
TocilizumabDrug
Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I and II: Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: From Baseline up to 4 weeks
- Part I, II and III: Percentage of Participants With Adverse Events (AEs)Time frame: From Baseline up to 90 days after last dose of study drug or until study completion or participant withdrawal (up to 5 years)
- Part II: MTD or OBD of GlofitamabTime frame: From Baseline up to 4 weeks
- Part II: Recommended Phase II Dose (RP2D) of GlofitamabTime frame: From Baseline up to 5 years
- Part III: Complete Response (CR) Rate as Assessed by Independent Review Committee (IRC) According to Standard Non-hodgkin's Lymphoma (NHL) Response Criteria (Lugano Classification)Time frame: From treatment start up to 5 years
- Part I, II and III: Area Under the Serum Concentration Versus Time Curve (AUC) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 71
- Part I, II and III: Maximum Serum Concentration (Cmax) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 198
- Part I, II and III: Minimum Serum Concentration (Cmin) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 up to Day 198
- Part I, II and III: Clearance (CL) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 71
- Part I, II and III: Volume of Distribution at Steady-state (Vss) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 71
- Part I, II and III: Half-life (t1/2) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 71
Locations
34 sites in 13 countries. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan
Washington University
St Louis, Missouri
Mount Sinai Medical Center
New York, New York
MSKCC
New York, New York
Allegheny Health Network (Pittsburg PA)
Pittsburgh, Pennsylvania
Swedish Cancer Inst.
Seattle, Washington
Prince of Wales Hospital
Randwick, New South Wales, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Cliniques Universitaires St-Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK
Prague, Czechia
Rigshospitalet
København Ø, Denmark
Helsinki University Central Hospital
Helsinki, Finland
Hopital Henri Mondor
Créteil, France
Hopital Claude Huriez
Lille, France
CHU Saint Eloi
Montpellier, France
Ch Lyon Sud
Pierre-Bénite, France
CHU DE RENNES - CHU Pontchaillou
Rennes, France
AUSL della Romagna
Ravenna, Emilia-Romagna, Italy
Fond. IRCCS Istituto Nazionale Tumori
Milan, Lombardy, Italy
Istituto Clinico Humanitas
Rozzano, Lombardy, Italy
Auckland Cancer Trial Centre
Auckland, New Zealand
Uniwersyteckie Centrum Kliniczne
Gda?sk, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu
Późna, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
Wroc?aw, Poland
Hospital del Mar
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Univ. 12 de Octubre
Madrid, Spain
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital Duran i Reynals L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
China Medical University Hospital
Taichung, Taiwan
National Taiwan Universtiy Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.